<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636255</url>
  </required_header>
  <id_info>
    <org_study_id>432715154</org_study_id>
    <nct_id>NCT04636255</nct_id>
  </id_info>
  <brief_title>Physical Capacity in Hodgkin Lymphoma Survivors</brief_title>
  <official_title>Physical Capacity Evaluation and Effects of ExerciseTraining on Hodgkin Lymphoma Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate if physical capacity obtained in the cardiopulmonary exercise&#xD;
      test can predict cardiovascular alterations in Hodgkin Lymphoma (HL) Survivors. In addition,&#xD;
      to study the effects of exercise training on physical capacity and cardiovascular responses&#xD;
      in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hodgkin Lymphoma (HL) is a hematological neoplasia that mainly affects young people.&#xD;
      Anthracycline-based chemotherapy, followed or not by mediastinal radiotherapy, substantially&#xD;
      improves prognosis in this set of patients. Observational studies have shown that&#xD;
      cardiovascular disease is the most non oncologic cause of death in this population. Coronary&#xD;
      artery disease (CAD) affects 26% of survivors after 10 years of absence of HL . However, the&#xD;
      early intervention and the assessment to predict the cardiovascular risk remain little known.&#xD;
      In this study, the investigators will test the hypothesis that physical capacity can predict&#xD;
      the cardiovascular alterations in HL Survivors. In addition, exercise training improves&#xD;
      physical capacity and heart rate responses in this set of patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2017</start_date>
  <completion_date type="Anticipated">April 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 21, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical Capacity - Peak oxygen consumption (mL/kg/min)</measure>
    <time_frame>4 months</time_frame>
    <description>Oxygen consuption in crescent effort will be calculated by aggregation of volume (mL), body weight (Kg) and time (minutes).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heart Hate (beat/min)</measure>
    <time_frame>4 months</time_frame>
    <description>Post-exercise heart rate will be evaluated by the number of beats in time masurement (one minute).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Function - Ejection Fraction</measure>
    <time_frame>4 months</time_frame>
    <description>Ejection Fraction (EF=ESV-EDV/EDV) combines end systolic (ESV) and diastolic volumes (EDV)(mL)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hodgkin Lymphoma, Adult</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Radiation Effect</condition>
  <condition>Chemotherapy Effect</condition>
  <arm_group>
    <arm_group_label>Exercise training group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental group, under clinic follow up will perform combined exercise training for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will be only clinically followed up. They will not perform exercise training.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physical Characteristics</intervention_name>
    <description>Body Weight, Height</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Exercise training group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Assessment of Heart rate variability</intervention_name>
    <description>Holter 24h</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Exercise training group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Pressure and Cardiac Autonomic Control</intervention_name>
    <description>Non-invasive photoplethysmography (Finometer® PRO) monitored by the electrocardiogram and respiratory frequency by a piezoelectric chest strap.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Exercise training group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Evaluation of Baroreflex Control</intervention_name>
    <description>The magnitude and latency of the baroreflex control of the heart rate will be assessed by bivariate analysis using the autoregressive method.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Exercise training group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac Function and Structure</intervention_name>
    <description>Echocardiogram</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Exercise training group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Assessment of Coronary Anatomy and Calcium Score</intervention_name>
    <description>Angiotomography</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Exercise training group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood Assessments</intervention_name>
    <description>Serum and Plasma will be extracted by centrifugation. NT-pro BNP (Roche™) and c-TnI (imunoassay Elecys 2010).</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Exercise training group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Physical Capacity</intervention_name>
    <description>Cardiopulmonary Exercise Test.</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>Exercise training group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Physical Training</intervention_name>
    <description>Aerobic exercise: 48 sessions of 60 minutes: 5 minutes of warm-up, 40 minutes of exercise. Resistance exercise: 10 minutes of exercise and 5 minutes of recovery.</description>
    <arm_group_label>Exercise training group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hodgkin Lymphoma Survivors&#xD;
&#xD;
          -  Over 18 years old&#xD;
&#xD;
          -  Chemotherapy with anthracycline and mediastinal radiotherapy in the last 5 years or&#xD;
             more&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Pregnant women,&#xD;
&#xD;
          -  Iodinated contrast allergy,&#xD;
&#xD;
          -  Life expectancy less than 1 year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos E Negrao, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto do Coracao, HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luciana S Santos</last_name>
    <phone>551126615043</phone>
    <email>gglusantos@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marilia RH Santos, PhD</last_name>
    <phone>551126615043</phone>
    <email>marilia.higuchi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Luciana de Souza Santos</name>
      <address>
        <city>Sao Paulo</city>
        <state>SP</state>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luciana de S Santos</last_name>
      <phone>551126615043</phone>
      <email>gglusantos@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Marilia RH Santos, PhD</last_name>
      <phone>551126615043</phone>
      <email>marilia.higuchi@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos E Negrao, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Ansell SM. Hodgkin Lymphoma: Diagnosis and Treatment. Mayo Clin Proc. 2015 Nov;90(11):1574-83. doi: 10.1016/j.mayocp.2015.07.005. Review.</citation>
    <PMID>26541251</PMID>
  </reference>
  <reference>
    <citation>Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, Tate DJ, Horning SJ, Hoppe RT, Hancock SL. Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol. 2007 Jan 1;25(1):43-9. Erratum in: J Clin Oncol. 2007 Apr 20;25(12):1635.</citation>
    <PMID>17194904</PMID>
  </reference>
  <reference>
    <citation>Gilchrist SC, Barac A, Ades PA, Alfano CM, Franklin BA, Jones LW, La Gerche A, Ligibel JA, Lopez G, Madan K, Oeffinger KC, Salamone J, Scott JM, Squires RW, Thomas RJ, Treat-Jacobson DJ, Wright JS; American Heart Association Exercise, Cardiac Rehabilitation, and Secondary Prevention Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Peripheral Vascular Disease. Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association. Circulation. 2019 May 21;139(21):e997-e1012. doi: 10.1161/CIR.0000000000000679.</citation>
    <PMID>30955352</PMID>
  </reference>
  <reference>
    <citation>Girinsky T, M'Kacher R, Lessard N, Koscielny S, Elfassy E, Raoux F, Carde P, Santos MD, Margainaud JP, Sabatier L, Ghalibafian M, Paul JF. Prospective coronary heart disease screening in asymptomatic Hodgkin lymphoma patients using coronary computed tomography angiography: results and risk factor analysis. Int J Radiat Oncol Biol Phys. 2014 May 1;89(1):59-66. doi: 10.1016/j.ijrobp.2014.01.021. Epub 2014 Mar 7.</citation>
    <PMID>24613809</PMID>
  </reference>
  <reference>
    <citation>Hoppe RT, Advani RH, Ai WZ, Ambinder RF, Aoun P, Bello CM, Bierman PJ, Blum KA, Chen R, Dabaja B, Duron Y, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Hochberg EP, Maloney DG, Mansur D, Mauch PM, Metzger M, Moore JO, Morgan D, Moskowitz CH, Poppe M, Pro B, Winter JN, Yahalom J, Sundar H; National Comprehensive Cancer Network. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 May;10(5):589-97.</citation>
    <PMID>22570290</PMID>
  </reference>
  <reference>
    <citation>Kavanagh T, Mertens DJ, Hamm LF, Beyene J, Kennedy J, Corey P, Shephard RJ. Prediction of long-term prognosis in 12 169 men referred for cardiac rehabilitation. Circulation. 2002 Aug 6;106(6):666-71.</citation>
    <PMID>12163425</PMID>
  </reference>
  <reference>
    <citation>Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van 't Veer MB, Baaijens MH, de Boer JP, Hart AA, Klokman WJ, Kuenen MA, Ouwens GM, Bartelink H, van Leeuwen FE. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007 Mar 1;109(5):1878-86. Epub 2006 Nov 21.</citation>
    <PMID>17119114</PMID>
  </reference>
  <reference>
    <citation>Koelwyn GJ, Jones LW, Moslehi J. Unravelling the causes of reduced peak oxygen consumption in patients with cancer: complex, timely, and necessary. J Am Coll Cardiol. 2014 Sep 30;64(13):1320-2. doi: 10.1016/j.jacc.2014.07.949.</citation>
    <PMID>25257632</PMID>
  </reference>
  <reference>
    <citation>Groarke JD, Tanguturi VK, Hainer J, Klein J, Moslehi JJ, Ng A, Forman DE, Di Carli MF, Nohria A. Abnormal exercise response in long-term survivors of hodgkin lymphoma treated with thoracic irradiation: evidence of cardiac autonomic dysfunction and impact on outcomes. J Am Coll Cardiol. 2015 Feb 17;65(6):573-83. doi: 10.1016/j.jacc.2014.11.035.</citation>
    <PMID>25677317</PMID>
  </reference>
  <reference>
    <citation>Wilson MG, Ellison GM, Cable NT. Basic science behind the cardiovascular benefits of exercise. Heart. 2015 May 15;101(10):758-65. doi: 10.1136/heartjnl-2014-306596. Review.</citation>
    <PMID>25911667</PMID>
  </reference>
  <reference>
    <citation>da Silva VP, de Oliveira NA, Silveira H, Mello RG, Deslandes AC. Heart rate variability indexes as a marker of chronic adaptation in athletes: a systematic review. Ann Noninvasive Electrocardiol. 2015 Mar;20(2):108-18. doi: 10.1111/anec.12237. Epub 2014 Nov 26. Review.</citation>
    <PMID>25424360</PMID>
  </reference>
  <reference>
    <citation>Cramer L, Hildebrandt B, Kung T, Wichmann K, Springer J, Doehner W, Sandek A, Valentova M, Stojakovic T, Scharnagl H, Riess H, Anker SD, von Haehling S. Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. J Am Coll Cardiol. 2014 Sep 30;64(13):1310-9. doi: 10.1016/j.jacc.2014.07.948.</citation>
    <PMID>25257631</PMID>
  </reference>
  <reference>
    <citation>Pumprla J, Howorka K, Groves D, Chester M, Nolan J. Functional assessment of heart rate variability: physiological basis and practical applications. Int J Cardiol. 2002 Jul;84(1):1-14. Review.</citation>
    <PMID>12104056</PMID>
  </reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>December 14, 2020</last_update_submitted>
  <last_update_submitted_qc>December 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oxygen Consumption</keyword>
  <keyword>Physical Training</keyword>
  <keyword>Heart Hate</keyword>
  <keyword>Cardioprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

